{"2572":{"id":2572,"qattrid":39,"type":1,"title":"B细胞在哪个淋巴器官中成熟？","result":"A","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"骨髓"},{"flag":"B","name":"胸腺"},{"flag":"C","name":"淋巴结"},{"flag":"D","name":"脾脏"}]},"2573":{"id":2573,"qattrid":39,"type":1,"title":"T细胞在哪个淋巴器官中成熟？","result":"B","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"骨髓"},{"flag":"B","name":"胸腺"},{"flag":"C","name":"淋巴结"},{"flag":"D","name":"脾脏"}]},"2574":{"id":2574,"qattrid":39,"type":1,"title":"B细胞具有以下哪种免疫功能？","result":"D","content":"免疫系统和功能-体液介导的免疫应答","options":[{"flag":"A","name":"向T细胞呈递抗原"},{"flag":"B","name":"产生多种促炎和调节性细胞因子"},{"flag":"C","name":"形成异位淋巴结构，如银屑病关节炎、类风湿关节炎"},{"flag":"D","name":"以上均是"}]},"2575":{"id":2575,"qattrid":39,"type":1,"title":"T细胞的主要功能是？","result":"C","content":"免疫系统和功能-细胞介导的免疫应答","options":[{"flag":"A","name":"杀死感染病毒的细胞"},{"flag":"B","name":"激活或帮助其他免疫细胞"},{"flag":"C","name":"杀死感染病毒的细胞和激活或帮助其他免疫细胞"},{"flag":"D","name":"以上均不是"}]},"2576":{"id":2576,"qattrid":39,"type":1,"title":"JAK的全称是？","result":"A","content":"免疫系统和功能-JAK-STAT通路","options":[{"flag":"A","name":"Janus激酶"},{"flag":"B","name":"酪氨酸激酶"},{"flag":"C","name":"蛋白激酶"},{"flag":"D","name":"磷酸激酶"}]},"2577":{"id":2577,"qattrid":39,"type":1,"title":"引起免疫应答的物质被称为：","result":"C","content":"免疫系统和功能-体液介导的免疫应答","options":[{"flag":"A","name":"抗体"},{"flag":"B","name":"表位"},{"flag":"C","name":"抗原"},{"flag":"D","name":"趋化因子"}]},"2578":{"id":2578,"qattrid":39,"type":1,"title":"IL-17家族的所有成员都被认为是促炎性的。","result":"A","content":"免疫系统和功能-IL-17家族","options":[{"flag":"A","name":"对 "},{"flag":"B","name":"错"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2579":{"id":2579,"qattrid":39,"type":1,"title":"免疫系统的哪些元素使细胞调节自身的生长和行为，募集其他免疫细胞，并确定感染部位？","result":"C","content":"免疫系统和功能-IL-17家族","options":[{"flag":"A","name":"中性粒细胞"},{"flag":"B","name":"嗜酸性粒细胞"},{"flag":"C","name":"细胞因子"},{"flag":"D","name":"趋化因子"}]},"2580":{"id":2580,"qattrid":39,"type":1,"title":"当细胞毒性 T 细胞的 T 细胞受体与另一细胞的 II 类 MHC 分子一起识别特异性抗原时，细胞毒性 T 细胞被激活。","result":"B","content":"免疫系统和功能-CD8+细胞毒性T细胞","options":[{"flag":"A","name":"对"},{"flag":"B","name":"错"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2581":{"id":2581,"qattrid":39,"type":1,"title":"酪氨酸激酶是一种酶，含有 :","result":"A","content":"免疫系统和功能-JAK-STAT通路","options":[{"flag":"A","name":"氨基酸"},{"flag":"B","name":"趋化因子"},{"flag":"C","name":"蛋白质"},{"flag":"D","name":"B细胞"}]},"2582":{"id":2582,"qattrid":39,"type":1,"title":"次级（或外周）淋巴器官储存淋巴细胞并启动固有免疫反应。这种说法正确吗？","result":"B","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2583":{"id":2583,"qattrid":39,"type":1,"title":"淋巴器官中包含免疫细胞聚集和相互作用的特殊结构。这种说法正确吗？","result":"A","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2584":{"id":2584,"qattrid":39,"type":1,"title":"免疫应答早期，哪两种细胞类型是主要炎症细胞？","result":"B","content":"免疫系统和功能-炎症反应","options":[{"flag":"A","name":"单核细胞和淋巴细胞"},{"flag":"B","name":"中性粒细胞和巨噬细胞"},{"flag":"C","name":"嗜酸性粒细胞额中性粒细胞"},{"flag":"D","name":"淋巴细胞和嗜碱性粒细胞"}]},"2585":{"id":2585,"qattrid":39,"type":1,"title":"引起免疫应答的物质被称为","result":"C","content":"免疫系统和功能-炎症反应","options":[{"flag":"A","name":"抗体"},{"flag":"B","name":"抗原决定簇"},{"flag":"C","name":"抗原"},{"flag":"D","name":"趋化因子"}]},"2586":{"id":2586,"qattrid":39,"type":1,"title":"每个抗原上的可识别位点称为：","result":"A","content":"免疫系统和功能-体液介导","options":[{"flag":"A","name":"抗原决定簇"},{"flag":"B","name":"B细胞受体"},{"flag":"C","name":"干细胞抗原"},{"flag":"D","name":"肽"}]},"2587":{"id":2587,"qattrid":39,"type":1,"title":"B细胞的受体可以识别多个表位。这种说法正确吗？","result":"B","content":"免疫系统和功能-体液介导","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2588":{"id":2588,"qattrid":39,"type":1,"title":"如果T细胞受体识别一特定抗原，此抗原与另一细胞的Ⅱ类MHC分子结合则这一细胞毒性T细胞就会激活。该说法正确吗？","result":"B","content":"免疫系统和功能-细胞介导","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2589":{"id":2589,"qattrid":39,"type":1,"title":"感染消退后，免疫应答结束，留下小部分_________ 变成记忆T细胞 。","result":"D","content":"免疫系统和功能-细胞介导","options":[{"flag":"A","name":"辅助性CD4+ T细胞"},{"flag":"B","name":"调节性 CD4+ T 细胞"},{"flag":"C","name":"常驻B 细胞"},{"flag":"D","name":"细胞毒性CD8+ T 细胞"}]},"2590":{"id":2590,"qattrid":39,"type":1,"title":"B细胞、T细胞、NK细胞都属于：","result":"C","content":"免疫系统和功能-免疫系统-细胞","options":[{"flag":"A","name":"粒细胞"},{"flag":"B","name":"单核细胞"},{"flag":"C","name":"淋巴细胞"},{"flag":"D","name":"以上均不是"}]},"2591":{"id":2591,"qattrid":39,"type":1,"title":"在感染部位， ___________ 吞噬感染颗粒和感染细胞。","result":"B","content":"免疫系统和功能-认识免疫系统","options":[{"flag":"A","name":"肥大细胞"},{"flag":"B","name":"中性粒细胞"},{"flag":"C","name":"嗜酸性粒细胞"},{"flag":"D","name":"嗜碱性粒细胞"}]},"2592":{"id":2592,"qattrid":39,"type":1,"title":"总抗体库中，占比最多的免疫球蛋白是？","result":"D","content":"免疫系统和功能-免疫球蛋白","options":[{"flag":"A","name":"IgA"},{"flag":"B","name":"IgM"},{"flag":"C","name":"IgE"},{"flag":"D","name":"IgG"}]},"2593":{"id":2593,"qattrid":39,"type":1,"title":"初次感染后出现的第一种抗体是：","result":"B","content":"免疫系统和功能-免疫球蛋白","options":[{"flag":"A","name":"IgA"},{"flag":"B","name":"IgM"},{"flag":"C","name":"IgD"},{"flag":"D","name":"IgE"}]},"2594":{"id":2594,"qattrid":39,"type":1,"title":"以下关于粒细胞系的说法，描述正确的是？","result":"A","content":"免疫系统和功能-免疫系统-细胞","options":[{"flag":"A","name":"粒细胞在骨髓中产生"},{"flag":"B","name":"粒细胞是含量很少白细胞，占所有循环白细胞的10%至20%"},{"flag":"C","name":"肥大细胞不属于粒细胞系细胞"},{"flag":"D","name":"嗜酸性粒细胞是数量最多的白细胞"}]},"2595":{"id":2595,"qattrid":39,"type":1,"title":"Th1、Th2、Th17和Treg通过树突状细胞与哪种细胞相互作用产生？","result":"A","content":"免疫系统和功能-细胞介导的免疫应答","options":[{"flag":"A","name":"初始CD4 +辅助性T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":"细胞毒性CD8+ T 细胞"},{"flag":"D","name":"淋巴细胞"}]},"2596":{"id":2596,"qattrid":39,"type":1,"title":"有关Tregs（调节性T细胞）说法错误的是？","result":"C","content":"免疫系统和功能-CD8+细胞毒性T细胞","options":[{"flag":"A","name":"是CD4 + T细胞的亚类"},{"flag":"B","name":"在外周耐受中起关键作用"},{"flag":"C","name":"通过已充分了解的机制抑制效应T细胞的增殖和细胞因子的产生"},{"flag":"D","name":"以上均是"}]},"2597":{"id":2597,"qattrid":39,"type":1,"title":"以下哪种细胞因子的信号传导作用与JAK1不相关？","result":"D","content":"免疫系统和功能-JAK-STAT通路","options":[{"flag":"A","name":" IL-2, IL-4，IFN α/β"},{"flag":"B","name":"IL-7, IL-9，IFN-γ"},{"flag":"C","name":"IL-15, IL-21，IL家族细胞因子, IL-10 家族细胞因子"},{"flag":"D","name":"IL-6 和其他gp130 细胞因子"}]},"2598":{"id":2598,"qattrid":39,"type":1,"title":"以下哪种细胞因子的信号传导作用与JAK2不相关？","result":"D","content":"免疫系统和功能-JAK-STAT通路","options":[{"flag":"A","name":"IFN-γ, IL-3, IL-5"},{"flag":"B","name":"GM-CSF, EPO, TPO"},{"flag":"C","name":" G-CSF, GH, 瘦素"},{"flag":"D","name":"IL-4, IL-7, IL-9,"}]},"2599":{"id":2599,"qattrid":39,"type":1,"title":"外周淋巴器官的作用是：","result":"B","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"产生淋巴细胞"},{"flag":"B","name":"维持淋巴细胞并启动获得性免疫反应"},{"flag":"C","name":"聚集淋巴细胞"},{"flag":"D","name":""}]},"2600":{"id":2600,"qattrid":39,"type":1,"title":"淋巴细胞被抗原激活的场所是：","result":"B","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"中央淋巴器官"},{"flag":"B","name":"外周淋巴器官"},{"flag":"C","name":"中央淋巴器官和外周淋巴器官"},{"flag":"D","name":""}]},"2601":{"id":2601,"qattrid":39,"type":1,"title":"哪类细胞与病原体结合后迁移至局部淋巴结激活获得性免疫反应？","result":"A","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"树突状细胞"},{"flag":"B","name":"中性粒细胞"},{"flag":"C","name":"自然杀伤细胞"},{"flag":"D","name":"辅助性T细胞"}]},"2602":{"id":2602,"qattrid":39,"type":1,"title":"中性粒细胞，巨噬细胞和树突状细胞都是：","result":"C","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"粒细胞"},{"flag":"B","name":"单核细胞"},{"flag":"C","name":"吞噬细胞"},{"flag":"D","name":"淋巴细胞"}]},"2603":{"id":2603,"qattrid":39,"type":1,"title":"哪类辅助性T细胞在细胞介导的免疫反应中起作用？","result":"B","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"Th0"},{"flag":"B","name":"Th1"},{"flag":"C","name":"Th2"},{"flag":"D","name":"Th8"}]},"2604":{"id":2604,"qattrid":39,"type":1,"title":"哪类白细胞可以产生抗体，与暴露在细胞表面的特异性靶点结合？","result":"A","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"B细胞"},{"flag":"B","name":"NK细胞"},{"flag":"C","name":"中性粒细胞"},{"flag":"D","name":"T细胞"}]},"2605":{"id":2605,"qattrid":39,"type":1,"title":"什么会导致疼痛和瘙痒（痒）？","result":"C","content":"免疫系统和功能-炎症反应","options":[{"flag":"A","name":"缓激肽刺激疼痛感受器时"},{"flag":"B","name":"蛋白质、体液和白细胞进入组织时"},{"flag":"C","name":"肥大细胞和活化的白细胞释放出作用于神经末梢的物质时"},{"flag":"D","name":"巨噬细胞释放趋化因子时"}]},"2606":{"id":2606,"qattrid":39,"type":1,"title":"有合成并储存组胺功能的是哪种白细胞？","result":"D","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"嗜酸性粒细胞"},{"flag":"B","name":"单核细胞"},{"flag":"C","name":"中性粒细胞"},{"flag":"D","name":"嗜碱性粒细胞"}]},"2607":{"id":2607,"qattrid":39,"type":1,"title":"与肥大细胞的结构和功能相似的是：","result":"B","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"嗜酸性粒细胞"},{"flag":"B","name":"嗜碱性粒细胞"},{"flag":"C","name":"B 细胞"},{"flag":"D","name":"树突状细胞"}]},"2608":{"id":2608,"qattrid":39,"type":1,"title":"哪类淋巴细胞可以识别外来因子并无需激活独立作用？","result":"D","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"B细胞"},{"flag":"B","name":"辅助性T细胞"},{"flag":"C","name":"毒性T细胞"},{"flag":"D","name":"NK细胞"}]},"2609":{"id":2609,"qattrid":39,"type":1,"title":"免疫反应过程中， ____________ 分化为效应细胞直接攻击抗原或辅助其他细胞，或分化为调节细胞以增强或减弱持续免疫应答。","result":"B","content":"免疫系统和功能-免疫系统细胞","options":[{"flag":"A","name":"B细胞"},{"flag":"B","name":"T细胞"},{"flag":"C","name":"中性粒细胞"},{"flag":"D","name":"吞噬细胞"}]},"2610":{"id":2610,"qattrid":39,"type":1,"title":"组织内部和组织间隙中聚集的清亮液体为：","result":"B","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"血浆"},{"flag":"B","name":"淋巴"},{"flag":"C","name":"白三烯B4"},{"flag":"D","name":"嗜酸性粒细胞"}]},"2611":{"id":2611,"qattrid":39,"type":1,"title":"一旦发现外来抗原，固有免疫系统的第一反应就是释放 ______________ 和其他引起局部炎症反应的化学因子。","result":"A","content":"免疫系统和功能-炎症反应","options":[{"flag":"A","name":"细胞因子"},{"flag":"B","name":"中性粒细胞"},{"flag":"C","name":"自然杀伤细胞"},{"flag":"D","name":"肥大细胞"}]},"2612":{"id":2612,"qattrid":39,"type":1,"title":"B细胞成熟和抗体分泌，对蛋白质抗原的应答需要以下协助：","result":"A","content":"免疫系统和功能-体液介导","options":[{"flag":"A","name":"辅助性T细胞"},{"flag":"B","name":"细胞毒性T细胞"},{"flag":"C","name":"自然杀伤细胞"},{"flag":"D","name":"巨噬细胞"}]},"2613":{"id":2613,"qattrid":39,"type":1,"title":"由B细胞产生的细胞因子 INFγ， IL-6，IL-10和TNF-α 参与：","result":"A","content":"免疫系统和功能-体液介导","options":[{"flag":"A","name":"巨噬细胞活化"},{"flag":"B","name":"B细胞分化"},{"flag":"C","name":"NK细胞活化"},{"flag":"D","name":"肥大细胞脱颗粒"}]},"2614":{"id":2614,"qattrid":39,"type":1,"title":"免疫球蛋白作为_________ 发挥作用并且由_________构成。","result":"C","content":"免疫系统和功能-细胞介导","options":[{"flag":"A","name":"淋巴细胞，淋巴液"},{"flag":"B","name":"抗原，白细胞"},{"flag":"C","name":"抗体，蛋白质"},{"flag":"D","name":"抗体，红细胞"}]},"2615":{"id":2615,"qattrid":39,"type":1,"title":"免疫系统用免疫球蛋白识别：","result":"B","content":"免疫系统和功能-细胞介导","options":[{"flag":"A","name":"细胞因子"},{"flag":"B","name":"病原体"},{"flag":"C","name":"淋巴细胞"},{"flag":"D","name":"趋化因子"}]},"2616":{"id":2616,"qattrid":39,"type":1,"title":"哪个T细胞亚型由其表达的CD8表面分子识别？","result":"B","content":"免疫系统和功能-细胞介导","options":[{"flag":"A","name":"辅助性T细胞"},{"flag":"B","name":"细胞毒性T细胞"},{"flag":"C","name":"抑制性T细胞"},{"flag":"D","name":"调节性T细胞"}]},"2617":{"id":2617,"qattrid":39,"type":1,"title":"哪种细胞因子促进幼稚CD4+ T 细胞向 Th1 细胞分化？","result":"C","content":"免疫系统和功能-细胞介导","options":[{"flag":"A","name":"IL-4"},{"flag":"B","name":"IL-6"},{"flag":"C","name":"IL-12"},{"flag":"D","name":"IL-23"}]},"2618":{"id":2618,"qattrid":39,"type":1,"title":"由Th1细胞分泌的主要细胞因子为：","result":"D","content":"免疫系统和功能-细胞介导","options":[{"flag":"A","name":"IL-23"},{"flag":"B","name":"IL-4"},{"flag":"C","name":"IL-17A"},{"flag":"D","name":"IFNγ"}]},"2619":{"id":2619,"qattrid":39,"type":2,"title":"以下有关免疫系统的说法，描述正确的是？","result":"A,B,C,D","content":"免疫系统和功能-前言","options":[{"flag":"A","name":"免疫系统是组织、器官、细胞及其化学介质之间复杂的相互关联"},{"flag":"B","name":"免疫系统的功能是保护机体免受感染、病毒、细菌或其他有害物质的侵害"},{"flag":"C","name":"免疫系统通过在病原体和机体之间铸成屏障来实现这一目的；如果病原体越过屏障，免疫系统则在它们开始繁殖之前监测和攻击它们；如果病原体开始繁殖，免疫系统则消除病原体"},{"flag":"D","name":"为了有效，免疫系统必须能够区分“自我”和“非自我”。"}]},"2620":{"id":2620,"qattrid":39,"type":2,"title":"细胞因子的关键种类包括：","result":"A,B,C,D","content":"免疫系统和功能-免疫应答-细胞因子","options":[{"flag":"A","name":"白细胞介素（ILs）"},{"flag":"B","name":"干扰素（IFNs）"},{"flag":"C","name":"肿瘤坏死因子(TNFs)"},{"flag":"D","name":"集落刺激因子（CSFs）"}]},"2621":{"id":2621,"qattrid":39,"type":2,"title":"CD8+ 细胞毒性T细胞：","result":"B,D","content":"免疫系统和功能-CD8+细胞毒性T细胞","options":[{"flag":"A","name":"与属于II类MHC的表位结合"},{"flag":"B","name":"与作为I类MHC一部分的表位结合"},{"flag":"C","name":"只有特定的细胞才能表达II类分子"},{"flag":"D","name":"几乎所有机体的细胞都表达I类分子"}]},"2622":{"id":2622,"qattrid":39,"type":2,"title":"Janus激酶(JAK)家族包括：","result":"A,B,C,D","content":"免疫系统和功能-JAK-STAT通路","options":[{"flag":"A","name":"JAK1"},{"flag":"B","name":"JAK2"},{"flag":"C","name":"JAK3"},{"flag":"D","name":"TYK2"}]},"2623":{"id":2623,"qattrid":39,"type":2,"title":"炎症的主要征兆是：","result":"A,B,C","content":"免疫系统和功能-炎症反应","options":[{"flag":"A","name":"发红和肿胀"},{"flag":"B","name":"发热和疼痛"},{"flag":"C","name":"功能丧失"},{"flag":"D","name":"脓液渗出"}]},"2624":{"id":2624,"qattrid":39,"type":2,"title":"B细胞还具有许多重要的免疫功能，包括：","result":"A,B,C","content":"免疫系统和功能-体液介导的免疫应答","options":[{"flag":"A","name":"具有向T细胞呈递抗原的强大能力"},{"flag":"B","name":"产生多种促炎和调节性细胞因子"},{"flag":"C","name":"具有形成异位淋巴结构的能力，可见于银屑病关节炎，类风湿关节炎和多发性硬化症患者"},{"flag":"D","name":""}]},"2625":{"id":2625,"qattrid":39,"type":2,"title":"T细胞作为获得性免疫的重要组成部分，其专门执行的两个主要功能是：","result":"C,D","content":"免疫系统和功能-免疫应答-获得性免疫","options":[{"flag":"A","name":"识别感染病毒的细胞"},{"flag":"B","name":"报告感染病毒的细胞"},{"flag":"C","name":"杀死感染病毒的细胞"},{"flag":"D","name":"激活或帮助其他免疫细胞"}]},"2626":{"id":2626,"qattrid":39,"type":2,"title":"被T细胞刺激后，活化的B细胞分化成：","result":"A,B","content":"免疫系统和功能-体液介导的免疫应答","options":[{"flag":"A","name":"浆细胞"},{"flag":"B","name":"记忆细胞"},{"flag":"C","name":"生发细胞"},{"flag":"D","name":""}]},"2627":{"id":2627,"qattrid":39,"type":2,"title":"在体内存在两种主要的T细胞亚型，它们是：","result":"A,B","content":"免疫系统和功能-细胞介导的免疫应答","options":[{"flag":"A","name":"CD4"},{"flag":"B","name":"CD8"},{"flag":"C","name":"CD16"},{"flag":"D","name":"CD20"}]},"2628":{"id":2628,"qattrid":39,"type":1,"title":"产生淋巴结的中心（或主要）淋巴器官为：","result":"A","content":"免疫系统和功能-淋巴系统","options":[{"flag":"A","name":"骨髓，胸腺，阑尾"},{"flag":"B","name":"扁桃体，淋巴结，脾脏"},{"flag":"C","name":"骨髓，胸腺，淋巴结"},{"flag":"D","name":"淋巴结，骨髓，阑尾"}]},"2629":{"id":2629,"qattrid":37,"type":1,"title":"根据最新2018年中国类风湿关节炎诊疗指南数据来看，我国大陆地区的RA总患病人群约为多少？","result":"B","content":"类风湿关节炎临床症状和体征-自身免疫性疾病-类风湿关节炎的发病机制","options":[{"flag":"A","name":"400万"},{"flag":"B","name":"500万"},{"flag":"C","name":"5000万"},{"flag":"D","name":"4000万"}]},"2630":{"id":2630,"qattrid":37,"type":1,"title":"RA患者具有什么样的临床表现？","result":"D","content":"类风湿关节炎临床症状和体征-自身免疫性疾病-类风湿关节炎的发病机制","options":[{"flag":"A","name":"关节肿胀、疼痛、活动受限"},{"flag":"B","name":"乏力、低烧、食欲不振，或仅表现为“全身不适”"},{"flag":"C","name":"结节增生，这些结节一般位于肘部或足部等骨骼区域的皮下 ；或伴有全身表现"},{"flag":"D","name":"以上均是"}]},"2631":{"id":2631,"qattrid":37,"type":1,"title":"增大的、病变的类风湿关节炎滑膜被称为：","result":"A","content":"类风湿关节炎病理生理学-类风湿关节炎的病理学概述","options":[{"flag":"A","name":"滑膜血管翳"},{"flag":"B","name":"炎症性滑膜"},{"flag":"C","name":"骨侵蚀"},{"flag":"D","name":"软骨侵蚀"}]},"2632":{"id":2632,"qattrid":37,"type":1,"title":"类风湿关节炎的诊断标准是：","result":"C","content":"类风湿关节炎临床症状和体征-类风湿关节炎病理生理学-危险因素","options":[{"flag":"A","name":"2010年ACR/EULAR标准"},{"flag":"B","name":"1987年ACR标准"},{"flag":"C","name":"2010年ACR/EULAR标准和1987年ACR标准"},{"flag":"D","name":"1987年ACR/EULAR标准和2010年ACR标准"}]},"2633":{"id":2633,"qattrid":37,"type":1,"title":"类风湿关节炎必有的临床特征是：","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"在长时间的坐姿或不活动之后发生僵硬"},{"flag":"B","name":"晨起时，晨起时关节活动不灵活，持续僵硬 1 小时或者更长的时间"},{"flag":"C","name":"疲劳、心神不安和抑郁"},{"flag":"D","name":"近端肌肉疼痛和压痛"}]},"2634":{"id":2634,"qattrid":37,"type":1,"title":"EULAR代表什么？","result":"A","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"欧洲抗风湿病联盟"},{"flag":"B","name":"欧洲的限制和法规"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2635":{"id":2635,"qattrid":37,"type":1,"title":"DAS代表什么？","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"关节炎诊断评分"},{"flag":"B","name":"疾病活动评分"},{"flag":"C","name":"疾病和症状评分"},{"flag":"D","name":""}]},"2636":{"id":2636,"qattrid":37,"type":1,"title":"ACR是什么?","result":"A","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"美国风湿病学会"},{"flag":"B","name":"澳大利亚风湿病学会"},{"flag":"C","name":"美国风湿病学院"},{"flag":"D","name":"澳大利亚风湿病学院"}]},"2637":{"id":2637,"qattrid":37,"type":1,"title":"SDAI代表什么？","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"次要疾病活动指数"},{"flag":"B","name":"简化疾病活动指数"},{"flag":"C","name":"急性病活动指数"},{"flag":"D","name":"疾病活动指数"}]},"2638":{"id":2638,"qattrid":37,"type":1,"title":"CDAI代表什么？","result":"D","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"次要疾病活动指数"},{"flag":"B","name":"简化疾病活动指数"},{"flag":"C","name":"急性病活动指数"},{"flag":"D","name":"疾病活动指数"}]},"2639":{"id":2639,"qattrid":37,"type":1,"title":"描述超级抗原的正确术语或短语是什么？","result":"B","content":"类风湿关节炎临床症状和体征-自身免疫失调","options":[{"flag":"A","name":"抗原呈递细胞所呈现的外来抗原的结构与自身抗原的结构相似"},{"flag":"B","name":"一个能缩短正常抗原呈递激活T细胞过程的物质家族"},{"flag":"C","name":"非抗原呈递细胞现在也能够表达B7"},{"flag":"D","name":"由 MHCs表达的病毒抗原也携带有会被错误识别为外来抗原的自身抗原"}]},"2640":{"id":2640,"qattrid":37,"type":1,"title":"描述失去应答的正确术语或短语是什么？","result":"C","content":"类风湿关节炎临床症状和体征-自身免疫失调","options":[{"flag":"A","name":"抗原呈递细胞所呈现的外来抗原的结构与自身抗原的结构相似"},{"flag":"B","name":"一个能缩短正常抗原呈递激活T细胞过程的物质家族"},{"flag":"C","name":"非抗原呈递细胞现在也能够表达B7"},{"flag":"D","name":"由 MHCs表达的病毒抗原也携带有会被错误识别为外来抗原的自身抗原"}]},"2641":{"id":2641,"qattrid":37,"type":1,"title":"描述MHC失调的正确术语或短语是什么？","result":"D","content":"类风湿关节炎临床症状和体征-自身免疫失调","options":[{"flag":"A","name":"抗原呈递细胞所呈现的外来抗原的结构与自身抗原的结构相似"},{"flag":"B","name":"一个能缩短正常抗原呈递激活T细胞过程的物质家族"},{"flag":"C","name":"非抗原呈递细胞现在也能够表达B7"},{"flag":"D","name":"由 MHCs表达的病毒抗原也携带有会被错误识别为外来抗原的自身抗原"}]},"2642":{"id":2642,"qattrid":37,"type":1,"title":"“完整的”疾病活动评分中包括多少个关节？","result":"C","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"10"},{"flag":"B","name":"28"},{"flag":"C","name":"44"},{"flag":"D","name":""}]},"2643":{"id":2643,"qattrid":37,"type":1,"title":"所有类风湿关节炎患者在诊断时都会存在有抗瓜氨酸肽抗体（ACPAs）和类风湿因子。对还是错？","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2644":{"id":2644,"qattrid":37,"type":1,"title":"以下哪项是患者记录测量的例子？","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"Sharp评分"},{"flag":"B","name":"健康评估问卷"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2645":{"id":2645,"qattrid":37,"type":1,"title":" 在类风湿关节炎的关节损伤的分类中，最著名的X射线方法是什么？","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"拉森评分"},{"flag":"B","name":"Sharp评分"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2646":{"id":2646,"qattrid":37,"type":1,"title":"在基于28个关节的疾病活动度评分中，什么分数表示中度疾病活动？","result":"B","content":"类风湿关节炎临床症状和体征-临床表现与评估","options":[{"flag":"A","name":">10和≤22"},{"flag":"B","name":">3.2和≤5.1"},{"flag":"C","name":">20和≤40"},{"flag":"D","name":""}]},"2647":{"id":2647,"qattrid":37,"type":1,"title":"在简化疾病活动指数（SDAI）评分中，什么分数表示中度疾病活动？","result":"C","content":"类风湿关节炎临床症状和体征-临床表现与评估","options":[{"flag":"A","name":">10和≤22"},{"flag":"B","name":">3.2和≤5.1"},{"flag":"C","name":">20和≤40"},{"flag":"D","name":""}]},"2648":{"id":2648,"qattrid":37,"type":1,"title":"在临床疾病活动指数（CDAI）评分中，什么分数表示中度疾病活动？","result":"A","content":"类风湿关节炎临床症状和体征-临床表现与评估","options":[{"flag":"A","name":">10和≤22"},{"flag":"B","name":">3.2和≤5.1"},{"flag":"C","name":">20和≤40"},{"flag":"D","name":""}]},"2649":{"id":2649,"qattrid":37,"type":1,"title":"哪些白细胞在类风湿关节炎患者的滑液中占主导地位（60-80%）？","result":"B","content":"类风湿关节炎临床症状和体征-临床表现与评估","options":[{"flag":"A","name":"嗜酸性粒细胞"},{"flag":"B","name":"中性粒细胞"},{"flag":"C","name":"嗜碱性粒细胞"},{"flag":"D","name":"巨噬细胞"}]},"2650":{"id":2650,"qattrid":37,"type":1,"title":"以下关于滑膜血管翳说法正确的是？","result":"A","content":"类风湿关节炎临床症状和体征-临床表现与评估","options":[{"flag":"A","name":"增大的、病变的类风湿关节炎滑膜被称为滑膜血管翳"},{"flag":"B","name":"血管翳仅能释放破坏软骨的酶，不会释放增强炎症的细胞因子"},{"flag":"C","name":"血管翳不会释放破坏软骨的酶，但会释放增强炎症的细胞因子"},{"flag":"D","name":"血管翳既不能能释放破坏软骨的酶，也不会释放增强炎症的细胞因子"}]},"2651":{"id":2651,"qattrid":37,"type":1,"title":"免疫系统对自身抗原的过度激活或不当激活，属于","result":"B","content":"类风湿关节炎临床症状和体征-自身免疫性疾病","options":[{"flag":"A","name":"过敏性疾病"},{"flag":"B","name":"自身免疫疾病"},{"flag":"C","name":"移植排异"},{"flag":"D","name":"免疫缺陷综合征 "}]},"2652":{"id":2652,"qattrid":37,"type":1,"title":"一个或多个组分的免疫功能异常，使得患者容易罹患那些可以受到完整的免疫系统预防的疾病，属于","result":"D","content":"类风湿关节炎临床症状和体征-自身免疫性疾病","options":[{"flag":"A","name":"过敏性疾病"},{"flag":"B","name":"自身免疫疾病"},{"flag":"C","name":"移植排异"},{"flag":"D","name":"免疫缺陷综合征 "}]},"2653":{"id":2653,"qattrid":37,"type":1,"title":"较男性而言，女性发生自身免疫性疾病通常会更为严重，死亡率也更高。该说法是否正确","result":"B","content":"类风湿关节炎临床症状和体征-自身免疫性疾病-流行病学及影响","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2654":{"id":2654,"qattrid":37,"type":1,"title":"机体通过什么机制消除潜在的自我反应性或自反应性 B 或 T细胞？","result":"C","content":"类风湿关节炎临床症状和体征-自身免疫性疾病-自身免疫性疾病的一般机制","options":[{"flag":"A","name":"中枢耐受性机制"},{"flag":"B","name":"外周耐受性机制"},{"flag":"C","name":"中枢耐受性和外周耐受性机制"},{"flag":"D","name":""}]},"2655":{"id":2655,"qattrid":37,"type":1,"title":"调节性 T 细胞可以释放_______，抑制自身反应性 T 细胞和 B 细胞的活性。","result":"A","content":"类风湿关节炎临床症状和体征-自身免疫性疾病-耐受能力的故障","options":[{"flag":"A","name":"细胞因子"},{"flag":"B","name":"趋化因子"},{"flag":"C","name":"抗体"},{"flag":"D","name":"免疫复合物"}]},"2656":{"id":2656,"qattrid":37,"type":1,"title":"以下关于超抗原说法正确的是？","result":"C","content":"类风湿关节炎临床症状和体征-自身免疫性疾病-耐受能力的故障","options":[{"flag":"A","name":"超抗原是一类可以延长正常抗原提呈过程给活化 T 细胞的物质"},{"flag":"B","name":"超抗原通过抗原提呈细胞正常的抗原处理和呈递途径激活 T 细胞"},{"flag":"C","name":"超抗原作为完整分子可以在肽结合域外直接与 MHC 相互作用"},{"flag":"D","name":"超抗原的目的似乎是将 MHC 和 T 细胞受体分开，以减少激活的 T 细胞"}]},"2657":{"id":2657,"qattrid":37,"type":1,"title":" RA 中异常免疫和炎症反应的焦点是________。","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎病理生理学","options":[{"flag":"A","name":"破骨细胞"},{"flag":"B","name":"滑膜"},{"flag":"C","name":"骨关节"},{"flag":"D","name":"关节软骨"}]},"2658":{"id":2658,"qattrid":37,"type":1,"title":"ACPA和RF，对 RA 的特异性程度是_______。","result":"A","content":"类风湿关节炎临床症状和体征-类风湿关节炎病理生理学","options":[{"flag":"A","name":"ACPA明显更高"},{"flag":"B","name":"RF明显更高"},{"flag":"C","name":"两者一样"},{"flag":"D","name":""}]},"2659":{"id":2659,"qattrid":37,"type":1,"title":" CD4 + 细胞分化成的各种亚型中，哪个不被认为是 RA 炎症的关键参与者？","result":"D","content":"类风湿关节炎临床症状和体征-类风湿关节炎病理生理学","options":[{"flag":"A","name":"Treg"},{"flag":"B","name":"Th1"},{"flag":"C","name":"Th17"},{"flag":"D","name":"Th22"}]},"2660":{"id":2660,"qattrid":37,"type":1,"title":"描述分子模拟的正确术语或短语是什么？","result":"A","content":"类风湿关节炎临床症状和体征-自身免疫失调","options":[{"flag":"A","name":"抗原呈递细胞所呈现的外来抗原的结构与自身抗原的结构相似"},{"flag":"B","name":"一个能缩短正常抗原呈递激活T细胞过程的物质家族"},{"flag":"C","name":"非抗原呈递细胞现在也能够表达B7"},{"flag":"D","name":"由 MHCs表达的病毒抗原也携带有会被错误识别为外来抗原的自身抗原"}]},"2661":{"id":2661,"qattrid":37,"type":1,"title":"关于健康评估问卷的残疾指数，残疾会被评估为多少种类型？","result":"A","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"8"},{"flag":"B","name":"4"},{"flag":"C","name":"2"},{"flag":"D","name":""}]},"2662":{"id":2662,"qattrid":37,"type":1,"title":"用Sharp法测量关节侵蚀和关节腔缩小时的手部面积分别是多少？","result":"A","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"29和27"},{"flag":"B","name":"27和29"},{"flag":"C","name":"5和4"},{"flag":"D","name":"4和5"}]},"2663":{"id":2663,"qattrid":37,"type":1,"title":"Sharp法和Sharp van der Heijde（SHS）中用X射线来评估关节损伤的方法有什么区别？","result":"D","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"The Sharp van der Heijde (SHS) 仅评估手部"},{"flag":"B","name":"The Sharp van der Heijde (SHS) 仅评估脚部"},{"flag":"C","name":"The Sharp van der Heijde (SHS) 仅评估手部"},{"flag":"D","name":"The Sharp van der Heijde (SHS) 评估手部和脚部"}]},"2664":{"id":2664,"qattrid":37,"type":1,"title":"具有成纤维细胞样细胞和巨噬细胞样细胞类型的是__________。","result":"D","content":"类风湿关节炎临床症状和体征-类风湿关节炎的病理生理学","options":[{"flag":"A","name":"软骨"},{"flag":"B","name":"淋巴细胞"},{"flag":"C","name":"吞噬细胞"},{"flag":"D","name":"滑膜细胞"}]},"2665":{"id":2665,"qattrid":37,"type":1,"title":"由中性粒细胞和巨噬细胞分泌的活性氧促进了 ______________。","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的病理生理学","options":[{"flag":"A","name":"类风湿因子复合物的形成"},{"flag":"B","name":"其他细胞的凋亡"},{"flag":"C","name":"骨沉积"},{"flag":"D","name":"吞噬作用"}]},"2666":{"id":2666,"qattrid":37,"type":1,"title":"由中性粒细胞和巨噬细胞分泌的自由基能促进 _____.","result":"B","content":"类风湿关节炎临床症状和体征-类风湿关节炎的病理生理学","options":[{"flag":"A","name":"抗体产生"},{"flag":"B","name":"其他细胞凋亡"},{"flag":"C","name":"骨沉积"},{"flag":"D","name":"吞噬作用"}]},"2667":{"id":2667,"qattrid":37,"type":1,"title":"以下哪个症状不是典型的 RA 症状？","result":"C","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"晨僵"},{"flag":"B","name":"手腕受累"},{"flag":"C","name":"远端指间关节受累"},{"flag":"D","name":"近端指间关节受累"}]},"2668":{"id":2668,"qattrid":37,"type":1,"title":"以下哪个标准不是用于诊断 2010 ACR/EULAR 分类的 RA？","result":"C","content":"类风湿关节炎临床症状和体征-类风湿关节炎的临床表现和评估","options":[{"flag":"A","name":"关节数量"},{"flag":"B","name":"症状持续时间"},{"flag":"C","name":"症状强度"},{"flag":"D","name":"类风湿因子(RF)"}]},"2669":{"id":2669,"qattrid":37,"type":2,"title":"根据免疫病理学可将疾病主要分为哪几大类？","result":"A,B,C,D","content":"类风湿关节炎临床症状和体征-自身免疫性疾病","options":[{"flag":"A","name":"过敏性疾病"},{"flag":"B","name":"自身免疫疾病"},{"flag":"C","name":"移植排异"},{"flag":"D","name":"免疫缺陷综合征 "}]},"2670":{"id":2670,"qattrid":37,"type":2,"title":"下列哪个关于类风湿因子的说法是错误的？请选择所有合适项。","result":"C,D","content":"类风湿关节炎临床症状和体征-类风湿关节炎的病理生理学","options":[{"flag":"A","name":"是一种自身抗体"},{"flag":"B","name":"能与IgG特异性结合，其复合物能激活补体"},{"flag":"C","name":"不会在健康人中发现"},{"flag":"D","name":"每个类风湿关节炎的患者，其类风湿因子的血液测试都是阳性的"}]},"2671":{"id":2671,"qattrid":37,"type":2,"title":"基于28个关节的疾病活动度评分中包括哪些测量内容？请选择所有合适项。","result":"A,B,C","content":"类风湿关节炎临床症状和体征-临床表现与评估","options":[{"flag":"A","name":"28个疼痛关节"},{"flag":"B","name":"28个肿胀关节"},{"flag":"C","name":"红细胞沉降率(ESR)或C反应蛋白(CRP)"},{"flag":"D","name":"患者疼痛的评估和患者身体功能的评估"}]},"2672":{"id":2672,"qattrid":37,"type":2,"title":"正常的免疫应答依赖于哪三个关键部分？","result":"A,B,D","content":"类风湿关节炎临床症状和体征-自身免疫性疾病-耐受能力的故障","options":[{"flag":"A","name":"抗原结构（自我和非自我）"},{"flag":"B","name":"T细胞受体识别抗原"},{"flag":"C","name":"B细胞受体识别抗原"},{"flag":"D","name":"MHC 提呈抗原的方式"}]},"2673":{"id":2673,"qattrid":37,"type":2,"title":"目前已探明，RA 发病过程中的关键细胞因子有_______。","result":"A,B,C","content":"类风湿关节炎临床症状和体征-类风湿关节炎病理生理学","options":[{"flag":"A","name":"TNFα"},{"flag":"B","name":"IL-6"},{"flag":"C","name":"IL-1"},{"flag":"D","name":"IL-17"}]},"2674":{"id":2674,"qattrid":35,"type":1,"title":"csDMARD 代表什么？","result":"A","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"传统合成改善病情抗风湿药"},{"flag":"B","name":"传统系统改善病情抗风湿药"},{"flag":"C","name":"传统靶向改善病情抗风湿药"},{"flag":"D","name":""}]},"2675":{"id":2675,"qattrid":35,"type":1,"title":"bDMARD代表什么？","result":"B","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"生物合成改善病情抗风湿药"},{"flag":"B","name":"生物制剂改善病情抗风湿药"},{"flag":"C","name":"生物类似物改善病情抗风湿药"},{"flag":"D","name":""}]},"2676":{"id":2676,"qattrid":35,"type":1,"title":"tsDMARD 代表什么？","result":"C","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"靶向合成生物制剂改善病情抗风湿药"},{"flag":"B","name":"系统靶向改善病情抗风湿药"},{"flag":"C","name":"靶向合成改善病情抗风湿药"},{"flag":"D","name":""}]},"2677":{"id":2677,"qattrid":35,"type":1,"title":"甲氨蝶呤属于哪类药物？","result":"A","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"csDMARD "},{"flag":"B","name":"bDMARD "},{"flag":"C","name":"tsDMARD "},{"flag":"D","name":"NSAIDs（非甾体抗炎药）"}]},"2678":{"id":2678,"qattrid":35,"type":1,"title":"TNF 抑制剂属于哪类药物？","result":"B","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"csDMARD "},{"flag":"B","name":"bDMARD "},{"flag":"C","name":"tsDMARD "},{"flag":"D","name":"NSAIDs（非甾体抗炎药）"}]},"2679":{"id":2679,"qattrid":35,"type":1,"title":"托法替布属于哪类药物？","result":"C","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"csDMARD "},{"flag":"B","name":"bDMARD "},{"flag":"C","name":"tsDMARD "},{"flag":"D","name":"NSAIDs（非甾体抗炎药）"}]},"2680":{"id":2680,"qattrid":35,"type":1,"title":"以下属于TNF 抑制剂的是？","result":"D","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"阿达木单抗和依那西普"},{"flag":"B","name":"戈利木单抗"},{"flag":"C","name":"英夫利昔单抗"},{"flag":"D","name":"以上全是"}]},"2681":{"id":2681,"qattrid":35,"type":1,"title":"以下哪个选项中的药物属于bDMARD？","result":"D","content":"类风湿关节炎治疗-RA治疗的发展历史","options":[{"flag":"A","name":"TNF-α抑制剂和B细胞靶向治疗"},{"flag":"B","name":"IL-6抑制剂和IL-1抑制剂"},{"flag":"C","name":"共刺激调节剂"},{"flag":"D","name":"以上均是"}]},"2682":{"id":2682,"qattrid":35,"type":1,"title":"尚杰®在中国说明书中的推荐剂量为？","result":"C","content":"类风湿关节炎治疗-附录-尚杰说明书","options":[{"flag":"A","name":"2mg"},{"flag":"B","name":"4mg"},{"flag":"C","name":"5mg"},{"flag":"D","name":"10mg"}]},"2683":{"id":2683,"qattrid":35,"type":1,"title":"尚杰®在中国说明书中的推荐给药频次为：","result":"A","content":"类风湿关节炎治疗-附录-尚杰说明书","options":[{"flag":"A","name":"每日两次"},{"flag":"B","name":"每日一次"},{"flag":"C","name":"每日3次"},{"flag":"D","name":""}]},"2684":{"id":2684,"qattrid":35,"type":1,"title":"临床研究中，接受依那西普治疗的患者一般在首次给药后多久出现临床反应 ?","result":"A","content":"类风湿关节炎治疗-附录-恩利说明书","options":[{"flag":"A","name":"1-2周"},{"flag":"B","name":"6周"},{"flag":"C","name":"12周"},{"flag":"D","name":"24周"}]},"2685":{"id":2685,"qattrid":35,"type":1,"title":"JAK 抑制剂可能抑制参与自身免疫疾病的许多细胞因子的信号传导。并且可能抑制天然和适应 性免疫系统的激活。","result":"A","content":"类风湿关节炎治疗-RA疗法类别明细.","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2686":{"id":2686,"qattrid":35,"type":1,"title":"阿达木单抗的商品名是","result":"A","content":"类风湿关节炎治疗-修美乐说明书","options":[{"flag":"A","name":"修美乐®"},{"flag":"B","name":"类克®"},{"flag":"C","name":"雅美罗®"},{"flag":"D","name":"恩利®"}]},"2687":{"id":2687,"qattrid":35,"type":1,"title":"依那西普的商品名是","result":"D","content":"类风湿关节炎治疗-恩利说明书","options":[{"flag":"A","name":"修美乐®"},{"flag":"B","name":"类克®"},{"flag":"C","name":"雅美罗®"},{"flag":"D","name":"恩利®"}]},"2688":{"id":2688,"qattrid":35,"type":1,"title":"英夫利昔单抗的商品名是","result":"B","content":"类风湿关节炎治疗-类克说明书","options":[{"flag":"A","name":"修美乐®"},{"flag":"B","name":"类克®"},{"flag":"C","name":"雅美罗®"},{"flag":"D","name":"恩利®"}]},"2689":{"id":2689,"qattrid":35,"type":1,"title":"戈利木单抗的商品名是","result":"C","content":"类风湿关节炎治疗-欣普尼说明书","options":[{"flag":"A","name":"类克®"},{"flag":"B","name":"雅美罗®"},{"flag":"C","name":"欣普尼®"},{"flag":"D","name":"尚杰®"}]},"2690":{"id":2690,"qattrid":35,"type":1,"title":"托珠单抗的商品名是","result":"B","content":"类风湿关节炎治疗-雅美罗说明书","options":[{"flag":"A","name":"类克®"},{"flag":"B","name":"雅美罗®"},{"flag":"C","name":"欣普尼®"},{"flag":"D","name":"尚杰®"}]},"2691":{"id":2691,"qattrid":35,"type":1,"title":"利妥昔单抗的商品名是","result":"A","content":"类风湿关节炎治疗-美罗华说明书","options":[{"flag":"A","name":"美罗华®"},{"flag":"B","name":"恩利®"},{"flag":"C","name":"尚杰®"},{"flag":"D","name":"艾乐明®"}]},"2692":{"id":2692,"qattrid":35,"type":1,"title":"托法替布的商品名是","result":"C","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"美罗华®"},{"flag":"B","name":"恩利®"},{"flag":"C","name":"尚杰®"},{"flag":"D","name":"艾乐明®"}]},"2693":{"id":2693,"qattrid":35,"type":1,"title":"巴瑞替尼的商品名是","result":"D","content":"类风湿关节炎治疗-艾乐明说明书","options":[{"flag":"A","name":"美罗华®"},{"flag":"B","name":"恩利®"},{"flag":"C","name":"尚杰®"},{"flag":"D","name":"艾乐明®"}]},"2694":{"id":2694,"qattrid":35,"type":1,"title":"修美乐®是哪个公司的产品","result":"C","content":"类风湿关节炎治疗-修美乐说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"艾伯维"},{"flag":"D","name":"罗氏"}]},"2695":{"id":2695,"qattrid":35,"type":1,"title":"恩利®是哪个公司的产品","result":"A","content":"类风湿关节炎治疗-恩利说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"艾伯维"},{"flag":"D","name":"罗氏"}]},"2696":{"id":2696,"qattrid":35,"type":1,"title":"类克®是哪个公司的产品","result":"C","content":"类风湿关节炎治疗-类克说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"西安杨森"},{"flag":"D","name":"罗氏"}]},"2697":{"id":2697,"qattrid":35,"type":1,"title":"欣普尼®是哪个公司的产品","result":"C","content":"类风湿关节炎治疗-欣普尼说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"西安杨森"},{"flag":"D","name":"罗氏"}]},"2698":{"id":2698,"qattrid":35,"type":1,"title":"雅美罗®是哪个公司的产品","result":"D","content":"类风湿关节炎治疗-雅美罗说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"西安杨森"},{"flag":"D","name":"罗氏"}]},"2699":{"id":2699,"qattrid":35,"type":1,"title":"美罗华®是哪个公司的产品","result":"D","content":"类风湿关节炎治疗-美罗华说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"西安杨森"},{"flag":"D","name":"罗氏"}]},"2700":{"id":2700,"qattrid":35,"type":1,"title":"尚杰®是哪个公司的产品","result":"A","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"西安杨森"},{"flag":"D","name":"罗氏"}]},"2701":{"id":2701,"qattrid":35,"type":1,"title":"艾乐明®是哪个公司的产品","result":"B","content":"类风湿关节炎治疗-艾乐明说明书","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"礼来"},{"flag":"C","name":"西安杨森"},{"flag":"D","name":"罗氏"}]},"2702":{"id":2702,"qattrid":35,"type":1,"title":"恩利®的给药方式是什么？","result":"A","content":"类风湿关节炎治疗-恩利说明书","options":[{"flag":"A","name":"皮下注射"},{"flag":"B","name":"静脉注射"},{"flag":"C","name":"皮下或静脉注射"},{"flag":"D","name":"口服"}]},"2703":{"id":2703,"qattrid":35,"type":1,"title":"尚杰®的给药方式是什么？","result":"D","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"皮下注射"},{"flag":"B","name":"静脉注射"},{"flag":"C","name":"皮下或静脉注射"},{"flag":"D","name":"口服"}]},"2704":{"id":2704,"qattrid":35,"type":1,"title":"类克®的给药方式是什么？","result":"A","content":"类风湿关节炎治疗-类克说明书","options":[{"flag":"A","name":"静脉注射"},{"flag":"B","name":"皮下注射"},{"flag":"C","name":"静脉注射或皮下注射"},{"flag":"D","name":""}]},"2705":{"id":2705,"qattrid":35,"type":1,"title":"修美乐®治疗类风湿关节炎成年患者的推荐剂量是多少？","result":"B","content":"类风湿关节炎治疗-修美乐说明书","options":[{"flag":"A","name":"单次给药80mg ，两周一次"},{"flag":"B","name":"单次给药40 mg ，两周一次"},{"flag":"C","name":"单次给药40 mg ，每月一次"},{"flag":"D","name":""}]},"2706":{"id":2706,"qattrid":35,"type":1,"title":"恩利®治疗类风湿关节炎成年患者的推荐剂量和给药方式","result":"C","content":"类风湿关节炎治疗-恩利说明书","options":[{"flag":"A","name":"每次50mg注射，每周两次"},{"flag":"B","name":"两次25mg注射，每周一次"},{"flag":"C","name":"每次50mg注射，每周一次或两次25mg注射，每3-4天一次"},{"flag":"D","name":""}]},"2707":{"id":2707,"qattrid":35,"type":1,"title":"下列哪个是 IL-6 抑制剂？","result":"A","content":"类风湿关节炎治疗-IL-6抑制剂","options":[{"flag":"A","name":"托珠单抗"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"依那西普"},{"flag":"D","name":"托法替布"}]},"2708":{"id":2708,"qattrid":35,"type":1,"title":"临床实验列出的最常见的导致尚杰®停药的不良反应是什么？ ","result":"B","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"注射部位反应"},{"flag":"B","name":"感染"},{"flag":"C","name":"头疼"},{"flag":"D","name":"呕吐"}]},"2709":{"id":2709,"qattrid":35,"type":1,"title":"欣普尼®治疗类风湿关节炎的使用剂量和给药方式是什么 ","result":"A","content":"类风湿关节炎治疗-欣普尼说明书","options":[{"flag":"A","name":"50 mg皮下注射，每月一次"},{"flag":"B","name":"50mg  皮下注射，每月两次"},{"flag":"C","name":"50mg  皮下注射，6周一次"},{"flag":"D","name":""}]},"2710":{"id":2710,"qattrid":35,"type":1,"title":"雅美罗®治疗类风湿关节炎成年患者的皮下给药的剂量方案是什么？","result":"B","content":"类风湿关节炎治疗-雅美罗说明书","options":[{"flag":"A","name":"162 mg 皮下注射，每月一次"},{"flag":"B","name":"162 mg 皮下注射，每周一次"},{"flag":"C","name":"162 mg 皮下注射，两周一次"},{"flag":"D","name":""}]},"2711":{"id":2711,"qattrid":35,"type":1,"title":"以下哪种药物在国内的说明书不包括类风湿关节炎这个适应症？","result":"C","content":"类风湿关节炎治疗-B细胞靶向治疗","options":[{"flag":"A","name":"托珠单抗"},{"flag":"B","name":"戈利木单抗"},{"flag":"C","name":"利妥昔单抗"},{"flag":"D","name":""}]},"2712":{"id":2712,"qattrid":35,"type":1,"title":"益赛普®是以下哪种生物制剂的生物仿制药？","result":"D","content":"类风湿关节炎治疗-生物仿制药","options":[{"flag":"A","name":"阿达木单抗"},{"flag":"B","name":"托珠单抗"},{"flag":"C","name":"英夫利昔单抗"},{"flag":"D","name":"依那西普"}]},"2713":{"id":2713,"qattrid":35,"type":1,"title":"尚杰®不适用于以下哪类患者？","result":"A","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"早期RA成年患者"},{"flag":"B","name":"对甲氨蝶呤疗效不足的中重度RA成年患者"},{"flag":"C","name":"对甲氨蝶呤无法耐受的中重度RA成年患者"},{"flag":"D","name":""}]},"2714":{"id":2714,"qattrid":35,"type":1,"title":"尚杰®清除是通过:","result":"C","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"肝"},{"flag":"B","name":"肾"},{"flag":"C","name":"70%肝，30%肾"},{"flag":"D","name":""}]},"2715":{"id":2715,"qattrid":35,"type":1,"title":"即使进行了剂量调整，尚杰®仍不能用于哪类患者？","result":"B","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"中度肝功能损伤"},{"flag":"B","name":"重度肝功能损伤"},{"flag":"C","name":"中度肾功能不全"},{"flag":"D","name":"重度肾功能不全"}]},"2716":{"id":2716,"qattrid":35,"type":1,"title":"尚杰®与以下哪种药物不存在联用受限？","result":"A","content":"类风湿关节炎治疗-尚杰说明书","options":[{"flag":"A","name":"甲氨蝶呤"},{"flag":"B","name":"生物制剂DMARDs"},{"flag":"C","name":"强效免疫抑制剂"},{"flag":"D","name":"环孢霉素"}]},"2717":{"id":2717,"qattrid":35,"type":1,"title":"艾乐明®的用法用量，描述错误的是：","result":"D","content":"类风湿关节炎治疗-艾乐明说明书","options":[{"flag":"A","name":"口服给药"},{"flag":"B","name":"餐时或空腹时均可"},{"flag":"C","name":"可以在一日中的任何时候给药"},{"flag":"D","name":"仅可在空腹时给药"}]},"2718":{"id":2718,"qattrid":35,"type":1,"title":"以下特殊患者中，艾乐明®无需进行剂量调整的是","result":"A","content":"类风湿关节炎治疗-艾乐明说明书","options":[{"flag":"A","name":"轻中度肝损伤患者"},{"flag":"B","name":"轻中度肾损伤患者"},{"flag":"C","name":"重度肾损伤患者"},{"flag":"D","name":"重度肝损伤患者"}]},"2719":{"id":2719,"qattrid":35,"type":1,"title":"艾乐明®的主要清除机制是","result":"B","content":"类风湿关节炎治疗-艾乐明说明书","options":[{"flag":"A","name":"肝"},{"flag":"B","name":"肾"},{"flag":"C","name":"胆汁"},{"flag":"D","name":"肝和肾"}]},"2720":{"id":2720,"qattrid":35,"type":1,"title":"ACR50 是什么意思?","result":"C","content":"类风湿关节炎治疗-类风湿关节炎的诊断","options":[{"flag":"A","name":"除了5个美国风湿病学会核心组标准中的至少3个标准外，疼痛关节数量改善了50%"},{"flag":"B","name":"疼痛和肿胀关节数量改善了50%"},{"flag":"C","name":"除了5个美国风湿病学会核心组标准中的至少3个标准外，疼痛关节和肿胀关节的数量改善了50%"},{"flag":"D","name":""}]},"2721":{"id":2721,"qattrid":35,"type":1,"title":"ACR70 是什么意思?","result":"C","content":"类风湿关节炎治疗-类风湿关节炎的诊断","options":[{"flag":"A","name":"除了5个美国风湿病学会核心组标准中的至少3个标准外，疼痛关节数量改善了70%"},{"flag":"B","name":"疼痛和肿胀关节数量改善了70%"},{"flag":"C","name":"除了5个美国风湿病学会核心组标准中的至少3个标准外，疼痛关节和肿胀关节的数量改善了70%"},{"flag":"D","name":""}]},"2722":{"id":2722,"qattrid":35,"type":1,"title":"根据欧洲抗风湿病联盟推荐，如果一种TNF抑制剂疗法无效，患者可能不会接受另一种TNF抑制剂 。","result":"B","content":"类风湿关节炎治疗-类风湿关节炎的诊断","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"2723":{"id":2723,"qattrid":35,"type":1,"title":"欧洲抗风湿联盟推荐类风湿关节炎活动期的患者监测频率为__________。","result":"A","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"每1-3 月"},{"flag":"B","name":"每6月"},{"flag":"C","name":"每12月"},{"flag":"D","name":""}]},"2724":{"id":2724,"qattrid":35,"type":2,"title":"深入明确 RA 病理生理学机制，以下哪几种药物属于生物制剂DMARDs?","result":"A,B,C,D","content":"类风湿关节炎治疗-RA治疗的发展历史","options":[{"flag":"A","name":"肿瘤坏死因子(TNF)抑制剂"},{"flag":"B","name":"IL-6抑制剂"},{"flag":"C","name":"IL-1抑制剂"},{"flag":"D","name":"B细胞靶向治疗"}]},"2725":{"id":2725,"qattrid":35,"type":2,"title":"生物制剂DMARDs的给药方式可以是：","result":"A,B","content":"类风湿关节炎治疗-RA治疗的发展历史","options":[{"flag":"A","name":"皮下注射"},{"flag":"B","name":"静脉注射"},{"flag":"C","name":"口服"},{"flag":"D","name":"吸入"}]},"2726":{"id":2726,"qattrid":35,"type":2,"title":"EULAR指南推荐的DMARDs类型包括：","result":"A,B,D","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"传统合成DMARDs"},{"flag":"B","name":"生物制剂DMARDs"},{"flag":"C","name":"生物仿制药DMARDs"},{"flag":"D","name":"靶向合成DMARDs"}]},"2727":{"id":2727,"qattrid":35,"type":2,"title":"以下属于靶向合成DMARDs的药物是：","result":"A,B","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"托法替布"},{"flag":"B","name":"巴瑞替尼"},{"flag":"C","name":"阿巴西普"},{"flag":"D","name":"英夫利昔单抗"}]},"2728":{"id":2728,"qattrid":35,"type":2,"title":"以下哪些可作为RA临床研究的评估工具？","result":"A,B,C,D","content":"类风湿关节炎治疗-类风湿关节炎的诊断","options":[{"flag":"A","name":"ACR20/50/70"},{"flag":"B","name":"DAS28/CDAI/SDAI"},{"flag":"C","name":"HAQ-DI"},{"flag":"D","name":"Sharp评分"}]},"2729":{"id":2729,"qattrid":35,"type":2,"title":"以下属于JAK抑制剂的药物是：","result":"A,B","content":"类风湿关节炎治疗-RA 疗法类别明细","options":[{"flag":"A","name":"托法替布"},{"flag":"B","name":"巴瑞替尼"},{"flag":"C","name":"阿达木单抗"},{"flag":"D","name":"利妥昔单抗"}]},"2730":{"id":2730,"qattrid":35,"type":2,"title":"2016 EULAR指南推荐的首选治疗方案为：","result":"A,B","content":"类风湿关节炎治疗-经典治疗流程推荐","options":[{"flag":"A","name":"单用甲氨蝶呤"},{"flag":"B","name":"甲氨蝶呤联合短期大剂量糖皮质激素"},{"flag":"C","name":"生物制剂DMARDs"},{"flag":"D","name":"单用来氟米特"}]},"2731":{"id":2731,"qattrid":35,"type":2,"title":"多个用于治疗RA的生物制剂DMARDs类型中，已在国内上市的品种类型有：","result":"A,B","content":"类风湿关节炎治疗-所有竞品和产品说明书","options":[{"flag":"A","name":"TNF-α抑制剂"},{"flag":"B","name":"IL-6抑制剂"},{"flag":"C","name":"IL-1抑制剂"},{"flag":"D","name":"B细胞靶向治疗"}]},"2732":{"id":2732,"qattrid":38,"type":1,"title":"在RA患者中，巴瑞替尼进行了多少项关键性3期临床试验？","result":"C","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"3 "},{"flag":"B","name":"4 "},{"flag":"C","name":"5 "},{"flag":"D","name":"6 "}]},"2733":{"id":2733,"qattrid":38,"type":1,"title":"巴瑞替尼的五项关键性3期临床试验的主要疗效指标是什么？","result":"A","content":"巴瑞替尼临床试验概述-何为主要疗效指标","options":[{"flag":"A","name":"ACR20应答"},{"flag":"B","name":"ACR50应答"},{"flag":"C","name":"ACR70应答"},{"flag":"D","name":""}]},"2734":{"id":2734,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼4mg组和安慰剂组的0-24周带状疱疹发生率_________。","result":"B","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2735":{"id":2735,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼4mg组和安慰剂组的0-12周带状疱疹发生率_________。","result":"B","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2736":{"id":2736,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼2mg组和安慰剂组的0-24周严重感染发生率_________。","result":"A","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2737":{"id":2737,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼2mg组和安慰剂组的0-12周严重感染发生率_________。","result":"A","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2738":{"id":2738,"qattrid":38,"type":1,"title":"巴瑞替尼的长期扩展试验 (RA-BEYOND)，将跟踪观察患者对巴瑞替尼治疗的反应，最长可延长至_______。","result":"C","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"24个月"},{"flag":"B","name":"36个月"},{"flag":"C","name":"48个月"},{"flag":"D","name":"52个月"}]},"2739":{"id":2739,"qattrid":38,"type":1,"title":"巴瑞替尼的以下3期研究中，在MTX-naive患者中进行的是？","result":"A","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"RA-BEGIN"},{"flag":"B","name":"RA-BEAM"},{"flag":"C","name":"RA-BUILD"},{"flag":"D","name":"RA-BEACON"}]},"2740":{"id":2740,"qattrid":38,"type":1,"title":"巴瑞替尼的以下3期研究中，在csDMARDs-IR患者中进行的是？","result":"C","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"RA-BEGIN"},{"flag":"B","name":"RA-BEAM"},{"flag":"C","name":"RA-BUILD"},{"flag":"D","name":"RA-BEACON"}]},"2741":{"id":2741,"qattrid":38,"type":1,"title":"巴瑞替尼的以下3期研究中，在TNFi-IR患者中进行的是？","result":"D","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"RA-BEGIN"},{"flag":"B","name":"RA-BEAM"},{"flag":"C","name":"RA-BUILD"},{"flag":"D","name":"RA-BEACON"}]},"2742":{"id":2742,"qattrid":38,"type":1,"title":"在下列哪个试验中，阿达木单抗（修美乐）被用作活性对照药物？","result":"B","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"RA-BEGIN"},{"flag":"B","name":"RA-BEAM"},{"flag":"C","name":"RA-BUILD"},{"flag":"D","name":"RA-BEACON"}]},"2743":{"id":2743,"qattrid":38,"type":1,"title":"对于CDAI与SDAI两种评分，两者存在区别的评分项是：","result":"D","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"压痛关节计数 (0~28)"},{"flag":"B","name":"肿胀关节计数 (0~28)"},{"flag":"C","name":"患者和医师对疾病活动的整体评分 (0 至 10.0 厘米 )"},{"flag":"D","name":"C 反应蛋白 (mg / dl)(0.1 至 10.0)"}]},"2744":{"id":2744,"qattrid":38,"type":1,"title":"RA-BEGIN试验的设计是怎样的？","result":"B","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"随机、双盲、安慰剂对照"},{"flag":"B","name":"随机、双盲、阳性药物对照"},{"flag":"C","name":"随机、双盲、安慰剂对照和阳性药物对照"},{"flag":"D","name":""}]},"2745":{"id":2745,"qattrid":38,"type":1,"title":"RA-BEAM试验的设计是怎样的？","result":"C","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"随机、双盲、安慰剂对照"},{"flag":"B","name":"随机、双盲、阳性药物对照"},{"flag":"C","name":"随机、双盲、安慰剂对照和阳性药物对照"},{"flag":"D","name":""}]},"2746":{"id":2746,"qattrid":38,"type":1,"title":"RA-BALANCE试验的设计是怎样的？","result":"A","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"随机、双盲、安慰剂对照"},{"flag":"B","name":"随机、双盲、阳性药物对照"},{"flag":"C","name":"随机、双盲、安慰剂对照和阳性药物对照"},{"flag":"D","name":""}]},"2747":{"id":2747,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的第24周ACR20应答率分别为？","result":"A","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"61%和42%"},{"flag":"B","name":"66%和39%"},{"flag":"C","name":"41%和21%"},{"flag":"D","name":"34%和13%"}]},"2748":{"id":2748,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的第12周DAS28-hsCRP≤3.2的患者百分比分别为？","result":"A","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"36%和17%"},{"flag":"B","name":"26%和9%"},{"flag":"C","name":"46%和24%"},{"flag":"D","name":"31%和11%"}]},"2749":{"id":2749,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的第12周DAS28-hsCRP<2.6的患者百分比分别为？","result":"B","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"36%和17%"},{"flag":"B","name":"26%和9%"},{"flag":"C","name":"46%和24%"},{"flag":"D","name":"31%和11%"}]},"2750":{"id":2750,"qattrid":38,"type":1,"title":"RA-BUILD试验中，第24周影像学结果显示，巴瑞替尼2mg组和安慰剂组mTSS分别较基线改变：","result":"A","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"0.33和0.70"},{"flag":"B","name":"0.70和0.33"},{"flag":"C","name":"0.47和0.30"},{"flag":"D","name":"0.30和0.47"}]},"2751":{"id":2751,"qattrid":38,"type":1,"title":"RA-BUILD试验中，第几周即显示巴瑞替尼2mg组和安慰剂组的肿胀关节计数出现了显著性差异？","result":"B","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"第1周"},{"flag":"B","name":"第2周"},{"flag":"C","name":"第4周"},{"flag":"D","name":"第8周"}]},"2752":{"id":2752,"qattrid":38,"type":1,"title":"RA-BUILD试验中，第几周即显示巴瑞替尼2mg组和安慰剂组的关节压痛计数出现了显著性差异？","result":"C","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"第1周"},{"flag":"B","name":"第2周"},{"flag":"C","name":"第4周"},{"flag":"D","name":"第8周"}]},"2753":{"id":2753,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼4mg组和安慰剂组的0-24周SAE发生率_________。","result":"A","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2754":{"id":2754,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼4mg组和安慰剂组的0-12周SAE发生率_________。","result":"C","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2755":{"id":2755,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的0-24周感染发生率_________。","result":"C","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2756":{"id":2756,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的0-12周SAE发生率_________。","result":"C","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2757":{"id":2757,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的0-24周严重感染发生率_________。","result":"C","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2758":{"id":2758,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的0-12周严重感染发生率_________。","result":"C","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2759":{"id":2759,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的0-24周恶性肿瘤发生率_________。","result":"A","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同，均无患者发生"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2760":{"id":2760,"qattrid":38,"type":1,"title":"RA-BUILD试验中，巴瑞替尼2mg组和安慰剂组的0-12周恶性肿瘤发生率_________。","result":"A","content":"巴瑞替尼临床试验概述-RA-BUILD试验","options":[{"flag":"A","name":"相同，均无患者发生"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2761":{"id":2761,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼2mg组和安慰剂组的第24周ACR20应答率分别为？","result":"A","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"45%和27%"},{"flag":"B","name":"49%和27%"},{"flag":"C","name":"23%和13%"},{"flag":"D","name":"20%和8%"}]},"2762":{"id":2762,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼2mg组和安慰剂组的第12周DAS28-hsCRP≤3.2的患者百分比分别为？","result":"A","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"24%和9%"},{"flag":"B","name":"11%和4%"},{"flag":"C","name":"20%和11%"},{"flag":"D","name":"11%和6%"}]},"2763":{"id":2763,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼2mg组和安慰剂组的第12周DAS28-hsCRP<2.6的患者百分比分别为？","result":"B","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"24%和9%"},{"flag":"B","name":"11%和4%"},{"flag":"C","name":"20%和11%"},{"flag":"D","name":"11%和6%"}]},"2764":{"id":2764,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼2mg组和安慰剂组的0-24周SAE发生率_________。","result":"C","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2765":{"id":2765,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼2mg组和安慰剂组的0-12周SAE发生率_________。","result":"C","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2766":{"id":2766,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼4mg组和安慰剂组的0-24周感染发生率_________。","result":"B","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2767":{"id":2767,"qattrid":38,"type":1,"title":"RA-BEACON试验中，巴瑞替尼4mg组和安慰剂组的0-12周SAE发生率_________。","result":"B","content":"巴瑞替尼临床试验概述-RA-BEACON试验","options":[{"flag":"A","name":"相同"},{"flag":"B","name":"更高，但无显著性差异"},{"flag":"C","name":"更低，但无显著性差异"},{"flag":"D","name":""}]},"2768":{"id":2768,"qattrid":38,"type":1,"title":"RA-BEGIN试验的随机分组人数为？","result":"A","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"584"},{"flag":"B","name":"1307"},{"flag":"C","name":"290"},{"flag":"D","name":"684"}]},"2769":{"id":2769,"qattrid":38,"type":1,"title":"RA-BUILD试验的随机分组人数为？","result":"C","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"584"},{"flag":"B","name":"1307"},{"flag":"C","name":"684"},{"flag":"D","name":"527"}]},"2770":{"id":2770,"qattrid":38,"type":1,"title":"RA-BALANCE试验的随机分组人数为？","result":"C","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"584"},{"flag":"B","name":"1307"},{"flag":"C","name":"290"},{"flag":"D","name":"684"}]},"2771":{"id":2771,"qattrid":38,"type":1,"title":"RA-BEACON试验的随机分组人数为？","result":"D","content":"巴瑞替尼临床试验概述-临床试验","options":[{"flag":"A","name":"584"},{"flag":"B","name":"1307"},{"flag":"C","name":"684"},{"flag":"D","name":"527"}]}}